Showing results (91-100 of 118) with videos related to

Sort By:
Pageof 12
Brachytherapy|January 30, 2015
Refining prostate seed brachytherapy: Comparing high-, intermediate-, and low-activity seeds for I-125 permanent seed prostate brachytherapyGuila Delouya, Pascal Bahary, Jean-François Carrier, et al.
Brachytherapy|January 8, 2018
A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failureDaniel Taussky, Stéphane Bedwani, Nissan Meissner, et al.
International Journal of Radiation Oncology, Biology, Physics|February 23, 2010
Comparison between high and low source activity seeds for I-125 permanent seed prostate brachytherapyGiuseppina Laura Masucci, David Donath, Audrey Tétreault-Laflamme, et al.
The Canadian Journal of Urology|December 3, 2008
Factors influencing treatment decisions in patients with low risk prostate cancer referred to a brachytherapy clinicDaniel Taussky, Aihua Liu, Michal Abrahamowicz, et al.
Brachytherapy|July 9, 2021
PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot studyThomas Reynaud, Lara Hathout, Damien Carignan, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|May 19, 2017
External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancerDavid Tiberi, George Rodrigues, Tom Pickles, et al.
Cureus|January 27, 2017
Stereotactic Body Radiotherapy for Inoperable Liver Tumors: Results of a Single Institutional ExperienceHussam Hijazi, Marie-Pierre Campeau, David Roberge, et al.
Cancers|July 27, 2022
Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-UpKevin Kaulanjan, Danny Lavigne, Fred Saad, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|July 12, 2017
Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitorsDaniel Taussky, Julie Piotte, Kevin C Zorn, et al.
Urologic Oncology|July 30, 2021
The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancerMike Wenzel, Charles Dariane, Fred Saad, et al.
Pageof 12